Clinical Trials Using CYP17 Inhibitor CFG920

Clinical trials are research studies that involve people. The clinical trials on this list are studying CYP17 Inhibitor CFG920. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • Dose-Escalation and Efficacy Study of LAE001 / Prednisone Plus Afuresertib Patients With m-CRPC

    The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic castration resistant prostate cancer (m-CRPC) patients who have progressed / drug resistant following prior standard care treatments of any anti-androgen. This study intends to identify the most appropriate combined doses of LAE001 / prednisone and afuresertib in m-CRPC patients who have progressive disease or are intolerant of 2 prior standard treatments of any anti-androgen or anti-androgen treatment plus chemotherapy.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois